Patient characteristics at baseline.
| Based on ActiveaJoints | Based on InvolvedbJoints | |||
|---|---|---|---|---|
| Oligoarthritis | Polyarthritis | Oligoarthritis | Polyarthritis | |
| No. of patients, n | 192 | 215 | 185 | 222 |
| Duration of follow-up, yrs | 9.3 (9.1) | 10.1 (8.7) | 9.2 (9.0) | 10.2 (8.8) |
| Males, n (%) | 117 (60.9) | 121 (56.3) | 112 (60.5) | 126 (56.8) |
| Age at psoriasis diagnosis, yrs | 29.1 (14.6) | 31.4 (16.1) | 28.6 (14.4) | 31.7 (16.0) |
| Age at PsA diagnosis, yrs | 42.5 (12.9) | 43.6 (13.3) | 42.0 (12.7) | 43.9 (13.4) |
| Duration of PsA, yrs | 0.4 (0.5) | 0.5 (0.7) | 0.4 (0.5) | 0.5 (0.7) |
| BMI | 28.5 (6.4) | 30.5 (7.8) | 28.3 (5.9) | 30.7 (8.1) |
| PASI | 4.0 (7.1) | 5.1 (9.3) | 4.1 (7.1) | 5.1 (9.2) |
| Actively inflamed joints | 1.8 (1.4) | 13.8 (9.5) | 1.8 (1.4) | 13.5 (9.6) |
| Dactylitis, % | 16.1 | 34.9 | 15.1 | 35.1 |
| Enthesitis, % | 16.1 | 28.8 | 16.2 | 28.4 |
| Axial disease, % | 11.5 | 17.2 | 10.8 | 17.6 |
| Extremities, % | ||||
| UE SJ | 42.2 | 87.9 | 42.2 | 88.3 |
| UE LJ | 19.3 | 54.4 | 18.9 | 55.0 |
| LE SJ | 22.4 | 78.1 | 23.2 | 78.8 |
| LE LJ | 21.4 | 50.7 | 20.0 | 51.8 |
| HAQ-DI | 0.4 (0.4) | 0.7 (0.6) | 0.4 (0.4) | 0.7 (0.6) |
| SF-36 PCS | 43.7 (10.5) | 37.0 (11.3) | 43.7 (10.5) | 37.1 (11.3) |
| SF-36 MCS | 45.5 (11.0) | 43.7 (10.5) | 45.6 (11.0) | 43.6 (10.5) |
| Highest medication, % | ||||
| NSAIDs | 34.9 | 28.8 | 35.7 | 28.4 |
| DMARDs | 13.5 | 17.7 | 13.0 | 18.0 |
| Biologics | 5.7 | 3.7 | 5.9 | 3.6 |
Values are expressed as mean (SD) unless otherwise indicated.
↵aActive joints: tender and/or swollen joints.
↵bInvolved joints: active and/or damaged joints. DMARD: disease-modifying antirheumatic drug; HAQ-DI: Health Assessment Questionnaire-Disability Index; LE: lower extremity; LJ: large joint; MCS: mental component summary score; NSAID: nonsteroidal antiinflammatory drugs; PASI: Psoriasis Area Severity Index; PCS: physical component summary score; PsA: psoriatic arthritis; SF-36: 36-item Short Form Health Survey; SJ: small joint; UE: upper extremity.